Inositol Meta-Analysis of 898 Patients Across 18 RCTs Shows Simultaneous Improvements in Insulin Resistance, Blood Pressure, Triglycerides

A systematic review published in Diabetology & Metabolic Syndrome on October 29, 2025 organized the clinical evidence for the inositol supplement category by pooling 18 RCTs with 898 participants. The headline reduces to one line. Inositol supplementation simultaneously improves insulin resistance, blood pressure, triglycerides, and BMI.

18 RCTs, 898 participants, 4-24 weeks

The meta-analysis included 18 RCTs covering 898 participants total. 428 in intervention groups, 421 in control groups. Trial durations ranged from 4 to 24 weeks, with most (11 trials) running 12 weeks or longer.

Inositol is a sugar alcohol close to the vitamin B family, with multiple molecular forms including myo-inositol and D-chiro-inositol. The most clinically validated is myo-inositol, first established in PCOS (polycystic ovary syndrome) trials. This meta-analysis suggests effect domains extending beyond PCOS into general metabolic health.

Eight key variables improved together

What gives this analysis weight is the multi-layered effect rather than single-variable effect.

BMI: -0.57 kg/m². For an average BMI of 25, the change is to about 24.4. Modest as a standalone effect, but meaningful when accompanying other improvements.

Waist circumference: -2.36 cm. Suggests partial reduction in visceral fat domain.

Fasting glucose: -7.25 mg/dL. Within normal range fluctuation, but meaningful change tied to insulin resistance.

Fasting insulin: -4.74 µU/mL. Reduction in insulin secretion itself.

HOMA-IR: -1.21. Standard indicator of insulin resistance. -1.21 is a clinically meaningful improvement size.

Triglycerides: -29.80 mg/dL. From an average of 150 mg/dL, a 30-point drop is clinically meaningful.

Systolic blood pressure: -5.34 mmHg. Meaningful improvement size by general guidelines.

Diastolic blood pressure: -6.12 mmHg. Meaningful change alongside systolic.

Supplements that simultaneously improve eight variables are uncommon. This is why inositol draws attention beyond PCOS in perimenopause, metabolic syndrome, and insulin resistance categories.

GRADE assessment, moderate certainty for insulin and HOMA-IR

The meta-analysis used GRADE (Grading of Recommendations Assessment, Development and Evaluation) to evaluate evidence certainty. Results varied by variable.

Moderate certainty: insulin, HOMA-IR. These two variables are classified as having effect sizes reliable enough for clinical use.

Low to very low certainty: other variables. Effect direction is consistent, but confidence in clinical significance is lower.

The implication is clear. Inositol’s insulin sensitivity improvement effect carries certainty usable for clinical decisions. Other effects (blood pressure, lipids, BMI) should be interpreted as supplementary, requiring more validation before serving as primary prescribing rationale.

Expansion from PCOS to perimenopause

Inositol’s clinical domain expanded in two stages. Stage one was PCOS. PCOS centers on insulin resistance and androgen excess, and inositol acts directly on insulin signaling, affecting both mechanisms. By 2026, it has settled as a standard PCOS supplement.

Stage two is perimenopause and metabolic syndrome. After menopause, estrogen decline accelerates loss of insulin sensitivity. Insulin resistance, weight gain, and elevated blood pressure often appear together in this window. Inositol becomes an option that acts on this multi-layered change as a single supplement.

Together with same-quarter perimenopausal data (elinzanetant NK receptor, Nestlé NAD+ booster, magnesium L-threonate cognitive scores), the perimenopausal supplement category sharpens at the mechanism level. Inositol holds a core role on the insulin sensitivity axis.

Dose and form

Doses commonly used in trials are 2-4 g/day myo-inositol. PCOS trials validated a 40:1 ratio combination of myo-inositol and D-chiro-inositol, derived from the hypothesis that this ratio approximates the natural human ratio.

Standard dosing splits into twice-daily administration. Evaluation is typical at 12 weeks or longer. The 11 trials of 12+ weeks duration in this meta-analysis showed larger effects.

Limits

Limits are clear. First, 18 RCTs is reasonable for a single analysis but can leave variable-specific subgroup analyses underpowered. Some variables show wide confidence intervals.

Second, most participants had PCOS or insulin resistance. Expecting comparable effect sizes in normal metabolic states is unreasonable. Inositol shows greater effects when metabolic abnormality is present.

Third, dietary insulin variables, exercise, and medication use varied across trials. Interactions between standalone inositol effects and other lifestyle variables require further validation.

Daily application

For consumers, the implication is concrete. With a PCOS diagnosis, inositol is a first-line supplement option. With postmenopausal insulin resistance or metabolic syndrome concerns, it serves as an adjunct option.

That said, inositol is a supplement rather than a prescription medication. Self-initiation is possible, but consultation with a physician or pharmacist before starting is recommended. If taking diabetes medications (metformin and similar), dose adjustment for hypoglycemia risk may be needed.